Lecture Details - Overview

Back to Lectures

Accreditation and Credit Designation

Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Difficult Cases in CML Management: How the Experts Treat Patients with CML

Sep 20, 2008, Phoenix, AZ

1 AMA PRA Category 1 Credit™
Release Date: October 31, 2008
Expiration Date: October 31, 2009

Lecture Overview

Description

This on-demand Webcast is from a satellite symposium held in conjunction with the Fifth Annual Symposium on Controversies and Clinical Challenges in Myeloma, Lymphoma, and Leukemia Congress held on September 20, 2008, in Phoenix, AZ.

Summary and Purpose

The Difficult Cases in CML Management: How the Experts Treat Patients With CML is designed to update physicians on challenging and practical issues in the treatment of CML and apprise them of the current recommendations for the optimal monitoring and management of patients with CML. Case discussions will address new therapeutic options in CML and treatment recommendations for patients with all phases of this disease as well as those with resistance or intolerance to first- and second-line options. Audience-submitted cases will be discussed in order to solve “real-world” problems, facilitating the transfer of knowledge into clinical practice. This symposium will provide a unique opportunity for the participants to directly interact with experts in the field.

Target Audience

This educational program is directed toward medical oncologists and hematologists. Nurses, fellows, and pharmacists in the oncology field who are interested in the treatment of cancer are also invited to participate. No specific skills or knowledge other than a basic training in oncology is required for successful participartion in this activity.

Learning Objectives

At the conclusion of this activity, you should be able to:

  • Describe advances in the diagnosis and treatment of patients with newly diagnosed CML, including the use of tyrosine kinase inhibitors to improve survival
  • Evaluate strategies for identifying resistance to kinase inhibitors in CML
  • Summarize early-stage to late or long-term molecular monitoring strategies and mutational analyses
  • Asses the role of novel ABL, Src, and Aurora kinase inhibitors in the management of ABL kinase inhibitor–resistant CML
  • Identify the supportive care therapies available for the optimal management of treatment- or disease-related adverse events

Instructions for Participation

  • Read the following information before beginning the educational activity.
  • Complete the Pretest.
  • View and study all Flash video presentations.
  • Complete the CME test.
  • Answer the evaluation questions.
  • After successful completion of the CME test and evaluation, you will receive your certificate online.
  • CME credit will be granted for online participation only.

Complete the test(s) and evaluation by October 31, 2009 to receive your certificate online.

Please scroll to the bottom and accept the CME Activity Terms in order to continue:

Disclosure Policy

It is the policy of Physicians' Education Resource to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians' Education Resource requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Physicians' Education Resource has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity.

These persons involved in the influence or control of content for the presentations from Difficult Cases in CML Management: How the Experts Treat Patients with CML symposium have disclosed the following relationship with the companies listed. The PER Scientific Content Team has no relevant financial relationships to disclose, unless noted below individually.

Michael J. Mauro, MD
Research Funding – Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation

Meir Wetzler, MD
Paid Consultant/Advisory Board – Bristol-Myers Squibb Company; Enzon Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation
Speaker's Bureau – Bristol-Myers Squibb Company; Enzon Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation

This CME activity might include discussion of investigational and/or unlabeled uses of drugs. If the activity includes discussion of investigational and/or unlabeled uses of a drug, specific information is delineated by the faculty during the presentation. Please refer to the full prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.

Software Requirements

The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser.

If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.

PC Users
If you need to upgrade your Web browser, follow one of the links listed below:

Macintosh Users
Compatible Web browsers include

Disclaimer

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views of the sponsor, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this activity to ensure accuracy, the faculty and Physicians' Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this activity, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.

Please consult full prescribing information for any drugs or procedures discussed within.

Privacy Policy

Physicians' Education Resource (PER) makes reasonable efforts to ensure that privacy issues are handled responsibly. PER does not sell or share your information with other organizations that are not directly involved in this process. If you have further concerns, you may contact us at (888) 949-0045.

All rights reserved. No part of this activity may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.

©Copyright 2008 by Physicians' Education Resource. No material may be reproduced in whole or in part, in any form, without written permission from the publisher.

All correspondence should be directed to:
Editor, Difficult Cases in CML Management: How the Experts Treat Patients with CML
Physicians' Education Resource
3500 Maple Ave.
Suite 700
Dallas, TX 75219
Phone: (214) 367-3400
Fax: (214) 367-3304
E-mail: editor@pergrouplp.com

Educational Grants

An educational grant for this activity was provided by:


  1. Novartis Oncology